Emerging role of gut microbiota in modulation of neuroinflammation and neurodegeneration with emphasis on Alzheimer's disease
| Autor: | Rakesh Singh, Syed Afroz Ali, Divya Goyal |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Disease
Gut flora Systemic inflammation digestive system 03 medical and health sciences 0302 clinical medicine Alzheimer Disease Brain-Gut Axis medicine Animals Humans Biological Psychiatry Neuroinflammation Pharmacology Intestinal permeability biology business.industry Probiotics digestive oral and skin physiology Neurodegeneration Brain medicine.disease biology.organism_classification 030227 psychiatry Gastrointestinal Microbiome stomatognathic diseases Neuroinflammatory Diseases Dysbiosis medicine.symptom Inflammation Mediators business Neuroscience Bacteriotherapy |
| Zdroj: | Progress in neuro-psychopharmacologybiological psychiatry. 106 |
| ISSN: | 1878-4216 |
| Popis: | Alzheimer's disease (AD) is a complex multifactorial disease involving chronic neuroinflammation and neurodegeneration. It has been recently recognized that gut microbiota interacts with the brain, and it is termed as microbiota-gut-brain axis. Modulation of this axis has been recently reported to affect the pathogenesis of neurodegenerative diseases, such as AD. Gut microbiota has a pivotal role in regulating multiple neuro-chemical pathways through the highly interconnected gut-brain axis. Recent emerging evidences have highlighted that the intestinal microflora takes part in bidirectional communication between the gut and the brain. Due to this, the researchers have suggested that human gut microflora may even act as the "second brain" and may be responsible for neurodegenerative disorders like Alzheimer's disease. Dysbiosis of gut microbiota can induce increased intestinal permeability and systemic inflammation. This may lead to the development of AD pathologies and cognitive impairment via the neural, immune, endocrine, and metabolic pathways. Thus, the modulation of gut microbiota through personalized diet, oral bacteriotherapy may lead to alteration of gut microbiota their products including amyloid protein. It has been demonstrated that modulation of the gut microbiota induces beneficial effects on neuronal pathways consequently leading to delay the progression of Alzheimer's disease. Thus, this approach may provide a novel therapeutic option for treatment of AD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect